Novartis has a much-anticipated approval for its spinal muscular atrophy (SMA) treatment onasemnogene abeparvovec in the US, getting a green light for a new version that can make more patients ...
Novartis’ AveXis unit has said European regulators have approved its Zolgensma (onasemnogene abeparvovec) gene therapy for the rare childhood wasting disease spinal muscular atrophy (SMA), and has ...
Top Guns Manager of The Decade Criteria: The PSN universes were created using the information collected through the PSN investment manager questionnaire and use only gross of fee returns. Mutual fund ...
SMA Solar Technology AG, together with its subsidiaries, develops, produces, and sells PV and battery inverters, monitoring systems for PV systems, and charging solutions for electric vehicles in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results